> ## Content Index
> Fetch the complete content index at: https://www.moatmarginresearch.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Cohance Lifesciences Moat Analysis: Score & Risks
- URL: https://www.moatmarginresearch.com/cohance-lifesciences-moat/
- Published: 2026-08-16T16:38:11.000Z
- Updated: 2026-08-22T05:13:47.000Z
- Author: A K Karthikeyan
- Tags: First-pass note, Coverage

Moat Note · First-pass

## Cohance Lifesciences Ltd.

A first-pass moat teardown of Cohance Lifesciences Ltd., built from single-pass filing evidence. Free note — provisional, and the full two-pass deep dive may revise it.

**Moat & Margin**16 Aug 2026 First-pass · \~3 min

5.15 / 10

NARROWProcess/Data-led

First-pass narrow read — primary edge in Cost Advantage. Provisional, single-pass evidence.

Provisional score · subject to modification based on new evidence

Cohance Lifesciences Ltd. scores **5.15** on MoatSCORE 6.0 — a narrow moat in Pharma. This is a **first-pass note**: the dimensional read and the filing receipts below come from a single GFIP evidence pass, not the full two-pass deep corpus behind our flagship deep dives. Provisional — published free while the deep version is queued.

The teardown 

## Seven dimensions of moat

Ordered by contribution. Each dimension carries a verified filing quote, graded **\[M\]** mechanism or **\[O\]** outcome.

D3Cost Advantage6

M · Mechanism✓ Verified verbatim

“The business remains supported by niche small to mid-volume products, diversified customer relationships, cost competitiveness, and backward integration capabilities.”

**Cohance Lifesciences Ltd.** · Earnings Call · p.3

D4Price Discretion5.7

M · Mechanism✓ Verified verbatim

“The Company has concluded that it is the principal in all its revenue arrangements since it is the primary obligor in all the revenue arrangements as it has pricing latitude and is”

**Cohance Lifesciences Ltd.** · Annual Report · p.95

D2Switching Costs5.5

M · Mechanism✓ Verified verbatim

“Quality and supply agreement, without that, no pioneering company will come back for any CDMO opportunity”

**Cohance Lifesciences Ltd.** · Earnings Call · p.18

D5Intangible Assets5

M · Mechanism✓ Verified verbatim

“Dr Prasada Raju's impressive academic background includes a PhD in chemistry, a PG Dip in patent law, and specialised training in material sciences at IIT, Chicago, USA.”

**Cohance Lifesciences Ltd.** · Annual Report · p.11

D1Network Effects4.8

M · Mechanism✓ Verified verbatim

“The additional advantage with Rising is its strong forte in distribution.”

**Cohance Lifesciences Ltd.** · Annual Report · p.6

D6Efficient Scale4.8

M · Mechanism✓ Verified verbatim

“Temporary disruption at Nacharam post OAI and subsequent Warning Letter led to \~₹55 crore shipment deferrals in the period”

**Cohance Lifesciences Ltd.** · Investor Presentation · p.6

D7Counter-PositioningExcluded—

Excluded for this archetype.

D8Ungoverned RiskUnscored · Layer 2.5

D8 rating: **ADEQUATE**. Not part of the moat score — it governs the cost of equity and the fade window. First-pass; not yet deep-reviewed.

The barrier gate 

## The barrier gate — first-pass

Replication — can a rival copy it?6.0

How hard it is for a rival to copy the edge (first-pass estimate).

Bypass — can a rival route around it?5.0

How easily a rival can route around the edge (first-pass estimate).

Effective barrier 5 — below 6, so the band is capped narrow. First-pass estimate.

What would change our mind

1. **Deep two-pass review.** This draft rests on a single GFIP evidence pass; the full 10-year AR + concall corpus may move the read.
2. **The barrier gate.** A firmer replication or bypass estimate is the most likely thing to shift the band.
3. **Adverse events.** Any governance, regulatory or funding shock captured in D8 could re-rate the fade window.

First-pass note — provisional single-pass MoatSCORE 6.0 read, not the full deep dive. Educational research, not investment advice; no buy/sell recommendation, no price target. Moat & Margin is not a SEBI-registered Research Analyst or Investment Adviser.

**Where this note fits.** This company is one of **509 Indian companies** we have scored for moat durability — 370 narrow, 126 narrow-trending-wide, none wide. Every score, dimension by dimension, is free in the [Moat Screener](https://www.moatmarginresearch.com/moat-screener/).